Andere talen XTL Biopharmaceuticals Ltd. Nasdaq

Aandelen

XTLB

US98386D3070

Vertraagde tijd Nasdaq Andere beurzen 17:32:30 22-05-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
2,67 ^USD	-4,64%		-2,55%	+164,33%

30/04	XTL Biopharmaceuticals Ltd. rapporteert resultaten voor het volledige jaar dat eindigde op 31 december 2023	CI
29/04	Top stijgers op de premarket	MT

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

XTL Biopharmaceuticals Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	30/04
Top Premarket Gainers	29/04
XTL Biopharmaceuticals : Report Of Foreign Private Issuer - Form 6-K	02/04
XTL Biopharmaceuticals : Immediate Report of Meeting	21/03
XTL Biopharmaceuticals : NOTICE OF EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON APRIL 30, 2024 - Form 6-K	21/03
XTL Biopharmaceuticals Ltd. announced that it expects to receive $1.5 million in funding	20/03
Top Midday Gainers	20/03
XTL Biopharmaceuticals to Acquire The Social Proxy; Shares Soar	20/03
XTL To Aquire The Social Proxy	20/03
XTL Biopharmaceuticals Ltd. entered into a binding term sheet to acquire THE SOCIAL PROXY Ltd.	20/03
XTL Biopharmaceuticals Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	15/11
XTL Biopharmaceuticals : Report Of Foreign Private Issuer - Form 6-K	15/11
XTL Biopharmaceuticals Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency	20-10-23
XTL Biopharmaceuticals : OPERATING AND FINANCIAL REVIEW AND PROSPECTS (Form 6-K)	25-08-21
XTL Biopharmaceuticals Ltd. Elects Alexander Rabinovitch as Directors	03-08-17
XTL Biopharmaceuticals Appoints Alex Rabinovich to its Board of Directors	27-04-17
XTL Biopharmaceuticals Ltd. Unveils Expanded hCDR1 Preclinical Data for the Treatment of Sjögren’s Syndrome	05-04-17
XTL Biopharmaceuticals Ltd. Announces Resignation David Kestenbaum as Chief Financial Officer	04-04-17
XTL Biopharmaceuticals Ltd. Reports Audited Consolidated Earnings Results for the Full Year Ended December 31, 2016	30-03-17
XTL Biopharmaceuticals Ltd. announced that it has received $2.8 million in funding	22-03-17

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen XTL Biopharmaceuticals Ltd. Nasdaq

Aandelen

XTLB

US98386D3070

Andere talen

Filters